advertisement
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (18)
Showing records 1 to 18
Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation28163 The effects of topical antiglaucoma on conjunctival impression cytology in malay glaucoma patients
Hoi TS; Nor MM; Hitam WHW; Jaafar H; Shatriah I
International Medical Journal 2010; 17: 271-274
28151 Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
Katz G; Springs CL; Craven ER; Montecchi-Palmer M
Clinical Ophthalmology 2010; 4: 1253-1261
28155 Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
Miyashiro MJ; Lo SC; Stewart JA; Stewart WC
Clinical Ophthalmology 2010; 4: 1355-1359
27915 Rare case of allergic blepharoconjuctivitis due to dorsolamide eyedrops
Urbancek S; Hazuchova H
Contact Dermatitis 2010; 63 SUPPL. 1 (65-66
28110 Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients
Renieri G; Fuhrer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 597-603
28045 Timolol maleate a gold standard drug in glaucoma used as ocular films and inserts: An overview
Rathore KS; Nema RK; Sisodia SS
International Journal of Pharmaceutical Sciences Review and Research 2010; 3: 23-29
28043 Preparation and evaluation of niosomes of brimonidine tartrate as ocular drug delivery system
Prabhu P; Koland M; Vijaynarayan K; Harish NM; Ganesh D; Charyulu RN; Satynarayana D
Journal of Pharmaceutical Research and Health Care 2010; 2: 293-301
28042 Preparation and evaluation of nano-vesicles of brimonidine tartrate as an ocular drug delivery system
Prabhu P; Kumar NR; Koland M; Harish NM; Vijayanarayan K; Dhondge G; Charyulu RN
Journal of Young Pharmacists 2010; 2: 356-361
28105 The role of benzalkonium chloride in the occurrence of punctate keratitis: A meta-analysis of randomized, controlled clinical trials
Trocme S; Hwang L-J; Bean GW; Sultan MB
Annals of Pharmacotherapy 2010; 44: 1914-1921
27813 Handiness and acceptability of the new Abak((registered trademark)) bottle in chronically treated patients. A cross-sectional, retrospective and multicentre study
Gabisson P; Briat B; Le Foll J; Conan S; Bale-Le Bescond F; Talmud M; Chibret H
Annales Pharmaceutiques Francaises 2011; 69: 22-29
27812 Ocular toxicity of benzalkonium
Chibret H
Annales Pharmaceutiques Francaises 2011; 69:108-115
27900 Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate
Gupta S; Vyas SP
Scientia Pharmaceutica 2010; 78: 959-976
28206 Newer approaches for optimal bioavailability of ocularly delivered drugs: Review
Kesavan K; Balasubramaniam J; Kant S; Singh PN; Pandit JK
Current Drug Delivery 2011; 8: 172-193
27912 Ocular intolerance to antiglaucoma medications is underestimated
Bresson-Dumont H
Bulletin de la Société Belge d'Ophtalmologie 2010; 315: 47-53
28090 Evaluating eye drop instillation technique in glaucoma patients
Gupta R; Patil B; Shah BM; Bali SJ; Mishra SK; Dada T
Journal of Glaucoma 2011; Epub ahead of print
28211 Ocular drug delivery - A look towards nanobioadhesives
Du Toit LC; Pillay V; Choonara YE; Govender T; Carmichael T
Expert Opinion on Drug Delivery 2011; 8: 71-94
27954 Drug delivery to the posterior segment of the eye
Kuppermann BD; Loewenstein A
Developments in Ophthalmology 2010; 47: 59-72
27957 A potential new therapeutic system for glaucoma: Solid lipid nanoparticles containing methazolamide
Li R; Jiang S; Liu D; Bi X; Wang F; Zhang Q; Xu Q
Journal of Microencapsulation 2011; 28: 134-141
